Q-omics provides the consensus-scored MIR205HG profile across patient tissues and cancer cell-line models. MIR205HG expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR205HG is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, MIR205HG RNA expression shows 12,874 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUSC, and TGCT as cancer lineages where MIR205HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR205HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR205HG survival associations across molecular data types. MIR205HG RNA expression shows survival associations in the most cancer types (19), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR205HG RNA expression–survival associations across cancer types. High MIR205HG expression shows unfavorable associations in KIRC, SKCM, PAAD and MESO, but favorable associations in BRCA and STAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR205HG RNA expression.
This table summarizes MIR205HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR205HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR205HG shows lower tumor expression in BRCA and KIRC and higher tumor expression in LUSC, UCEC, HNSC and PAAD. The LUSC box plot shows higher MIR205HG RNA expression in tumor versus normal tissue (log2 FC = +4.578, t-test p < 0.001).
This table shows molecular features associated with MIR205HG in patient tissues and cancer cell lines. In patient samples, MIR205HG shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MIR205HG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
